Eventide Asset Management LLC Makes New $28.07 Million Investment in MBX Biosciences, Inc. $MBX

Eventide Asset Management LLC purchased a new position in shares of MBX Biosciences, Inc. (NASDAQ:MBX) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 890,000 shares of the company’s stock, valued at approximately $28,071,000.

Other large investors have also recently bought and sold shares of the company. Hudson Bay Capital Management LP acquired a new position in MBX Biosciences during the 3rd quarter worth approximately $1,488,000. Ghisallo Capital Management LLC acquired a new position in MBX Biosciences during the 3rd quarter worth approximately $669,000. Aaron Wealth Advisors LLC boosted its position in MBX Biosciences by 40.0% during the 4th quarter. Aaron Wealth Advisors LLC now owns 70,000 shares of the company’s stock worth $2,208,000 after acquiring an additional 20,000 shares during the last quarter. Goelzer Investment Management Inc. acquired a new position in MBX Biosciences during the 4th quarter worth approximately $6,992,000. Finally, Baker BROS. Advisors LP acquired a new position in MBX Biosciences during the 3rd quarter worth approximately $4,861,000.

MBX Biosciences Trading Down 4.7%

MBX opened at $35.51 on Friday. MBX Biosciences, Inc. has a 1-year low of $9.43 and a 1-year high of $45.85. The stock’s fifty day simple moving average is $32.49 and its 200 day simple moving average is $32.97. The stock has a market cap of $1.69 billion, a PE ratio of -16.07 and a beta of 0.75.

MBX Biosciences (NASDAQ:MBX) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.15. Equities analysts forecast that MBX Biosciences, Inc. will post -2.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

MBX has been the subject of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MBX Biosciences in a research report on Tuesday, April 21st. Lifesci Capital raised MBX Biosciences to a “strong-buy” rating in a research report on Tuesday, March 31st. UBS Group reaffirmed a “buy” rating on shares of MBX Biosciences in a research report on Tuesday, February 24th. Citizens Jmp increased their price objective on MBX Biosciences from $76.00 to $86.00 and gave the company a “market outperform” rating in a report on Tuesday, May 12th. Finally, Stifel Nicolaus set a $56.00 price objective on MBX Biosciences in a report on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.22.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.